<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095238</url>
  </required_header>
  <id_info>
    <org_study_id>CV131-148</org_study_id>
    <nct_id>NCT00095238</nct_id>
  </id_info>
  <brief_title>Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)</brief_title>
  <official_title>Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if Irbesartan is superior to placebo
      in reducing mortality and cardiovascular morbidity in subjects with heart failure with
      preserved systolic function. The safety of this treatment will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to first occurrence of composite outcome of all-cause death (composite outcome of death) or protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include those ≥24 hrs or involving a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular or atrial dysrhythmia, or stroke, that also require intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. In addition, MI or stroke during any hospitalization are included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time Points</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to heart failure mortality or heart failure hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Month 6 and Month 14</measure>
    <time_frame>Baseline, Month 6, Month 14</time_frame>
    <description>Mean score and adjusted mean change from baseline in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Final Visit</measure>
    <time_frame>Baseline, Final Visit=last scheduled visit specified in the protocol at conclusion of the entire study by the sponsor. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>Mean score at baseline and final visit in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in B-Type Natriuretic Peptide (Pro-BNP) at Month 6 and Month 14</measure>
    <time_frame>Baseline, Month 6, Month 14</time_frame>
    <description>Adjusted ratio to baseline in geometric mean in Pro-BNP in the blood. Ratio to Baseline = On-therapy geometric mean divided by baseline geometric mean. A lower score signifies improvement. Change from baseline adjusted for baseline value and angiotensin converting enzyme inhibitor use at baseline. Analysis uses natural logarithms of excretion rate values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing CV Death, Non-Fatal Myocardial Infarction (MI), or Non-Fatal Stroke at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to cardiovascular death, non-fatal MI, or non-fatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Cardiovascular Death at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing All-cause Death at Given Time Points</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the New York Heart Association (NYHA) Functional Class at Month 6, Month 10, Month 14, and Final Visit</measure>
    <time_frame>Baseline, Month 6, Month 10, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>NYHA functional classification=4-tiered system relating symptoms to everyday activities &amp; quality of life. (See Reporting Groups for description of each class.) Change of NYHA functional class from baseline was grouped into 3 categories: improved, unchanged, or worsened (based on case report form [CRF] assessment). If a post-randomization CRF assessment was missing or participant died, was hospitalized for worsening heart failure or discontinued study medication for worsening heart failure, the participant was classified as Major Event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</measure>
    <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>This was an assessment of the change in overall physician opinion of change from baseline status. Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</measure>
    <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment of Fatigue at Month 6, Month 14, and Final Visit Compared With Baseline</measure>
    <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Assessment of Dyspnea at Month 6, Month 14, and Final Visit Compared With Baseline</measure>
    <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
    <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing CV Death or CV Hospitalization at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to CV death or CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Protocol-specified Cardiovascular (CV) Hospitalization at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Onset of Diabetes Among Subjects With No Prior Diabetes History at Given Timepoints</measure>
    <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
    <description>Treatment comparisons for time to new onset of diabetes (from adverse event reporting) among subjects with no prior history of diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Glomerular Filtration Rate (GFR) at Month 6, Month 18, and Month 30</measure>
    <time_frame>Baseline, Month 6, Month 18, Month 30</time_frame>
    <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Glomerular Filtration Rate (GFR)at Month 42, Month 54, Month 66</measure>
    <time_frame>Baseline, Month 42, Month 54, Month 66</time_frame>
    <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Onset Atrial Fibrillation (AF) Among Those With No Prior AF History or Evidence of AF on Baseline Electrocardiograph (ECG)</measure>
    <time_frame>Baseline, Final Visit</time_frame>
    <description>Frequency of new onset AF in participants with no prior AF history or evidence of AF on baseline ECG. Stratified by use of angiotensin-converting enzyme (ACE) inhibitors and measured by adverse events reporting and final ECG recording read by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4128</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age &gt;= 60 years with current symptoms of heart failure consistent with
             New York Heart Association (NYHA) class II-IV

          -  Left ventricular ejection fraction (LVEF) &gt; = 45%

          -  Willing to provide written informed consent AND hospitalization for heart failure
             within the past 6 months OR various abnormalities in electrocardiogram, echocardiogram
             or chest x-ray indicating heart disease.

        Exclusion Criteria:

          -  Acute myocardial infarction within 3 months;

          -  Heart revascularization procedure within 3 months;

          -  Hospitalization for angina within 3 months;

          -  Other heart surgery

          -  Life-threatening or uncontrolled arrhythmia

          -  Subjects with an implantable cardioverter-defibrillator that has discharged in the
             past 3 months;

          -  Stroke or surgery of the arteries in the brain within 3 months;

          -  Serious lung disease which requires use of home oxygen.

          -  Significantly low blood pressure

          -  Significantly high blood pressure

          -  Other known diseases that may limit life expectancy to &lt;3 years;

          -  Known or suspected bilateral kidney artery narrowing;

          -  Geographic or social factors making study participation and follow-up impractical.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chalmette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lorain</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Flourtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lynchberg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>South Boston</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Garran</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>AYE</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Borgerhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Genk-waterschei</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>HUY</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goiania-go</city>
        <state>Goias</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo, Sp</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rexdale</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St-Lambert</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Usti Nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Copenhagen Nv</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Abbeville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>DAX</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>GAP</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Langres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montbeliard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Provins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Malo</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gunzenhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Homburg / Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siofok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>County Dublin</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Pedro Garza Garcia</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hengelo Ov</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vlaardingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baerum Postterminal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tonsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Piotrkow Tryb.</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stalowa Wola</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Morningside</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parktown West</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berea</city>
        <state>Kwa Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Congella</city>
        <state>Kwa Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Skelleftea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zuerich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <state>Dumbartonshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hull</city>
        <state>Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>York</city>
        <state>Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Londonderry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <results_reference>
    <citation>Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.</citation>
    <PMID>19001508</PMID>
  </results_reference>
  <results_reference>
    <citation>Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30;121(12):1393-405. doi: 10.1161/CIRCULATIONAHA.109.909614. Epub 2010 Mar 15.</citation>
    <PMID>20231531</PMID>
  </results_reference>
  <results_reference>
    <citation>McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb;10(2):149-56. doi: 10.1016/j.ejheart.2007.12.010.</citation>
    <PMID>18279770</PMID>
  </results_reference>
  <results_reference>
    <citation>Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct;11(8):576-85.</citation>
    <PMID>16230259</PMID>
  </results_reference>
  <results_reference>
    <citation>McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 2009 Nov 4.</citation>
    <PMID>20142024</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2004</study_first_submitted>
  <study_first_submitted_qc>November 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2004</study_first_posted>
  <results_first_submitted>December 16, 2009</results_first_submitted>
  <results_first_submitted_qc>May 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2010</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Irbesartan</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2067">number randomized</participants>
                <participants group_id="P2" count="2061">number randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety (Treated) Population</title>
              <participants_list>
                <participants group_id="P1" count="2064">Two participants were randomized but not treated; 1 randomized to irbesartan received placebo</participants>
                <participants group_id="P2" count="2062">One participant randomized to irbesartan received placebo.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1210">completed double-blind therapy</participants>
                <participants group_id="P2" count="1209">completed double-blind therapy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="857"/>
                <participants group_id="P2" count="852"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Irbesartan</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2067"/>
            <count group_id="B2" value="2061"/>
            <count group_id="B3" value="4128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="376"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="981"/>
                    <measurement group_id="B3" value="1975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="697"/>
                    <measurement group_id="B2" value="716"/>
                    <measurement group_id="B3" value="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.6" spread="6.90"/>
                    <measurement group_id="B2" value="71.7" spread="7.00"/>
                    <measurement group_id="B3" value="71.6" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1227"/>
                    <measurement group_id="B2" value="1264"/>
                    <measurement group_id="B3" value="2491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="840"/>
                    <measurement group_id="B2" value="797"/>
                    <measurement group_id="B3" value="1637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1934"/>
                    <measurement group_id="B2" value="1925"/>
                    <measurement group_id="B3" value="3859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>1 participant in Placebo was not classified. NYHA Classes: I=No limitation of physical activity (does not cause undue fatigue, palpitation, or dyspnea). II=Slight limitation of physical activity (comfortable at rest, ordinary physical activity results in fatigue, palpitation, or dyspnea). III=Marked limitation of physical activity (comfortable at rest, less than ordinary activity causes fatigue, palpitation, or dyspnea). IV=Unable to carry out any physical activity without discomfort (symptoms of cardiac insufficiency at rest; discomfort is increased if any physical activity is undertaken).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="444"/>
                    <measurement group_id="B3" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1582"/>
                    <measurement group_id="B2" value="1562"/>
                    <measurement group_id="B3" value="3144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>B-Type Natriuretic Peptide (Pro-BNP)</title>
          <description>Participant population=those participants with a baseline Pro-BNP measurement. Irbesartan (n=1765), Placebo (n=1798), Total (n=3563)</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363.0" lower_limit="140.0" upper_limit="994.0"/>
                    <measurement group_id="B2" value="345.2" lower_limit="131.0" upper_limit="948.0"/>
                    <measurement group_id="B3" value="353.9" lower_limit="135.0" upper_limit="974.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints</title>
        <description>Treatment comparisons for time to first occurrence of composite outcome of all-cause death (composite outcome of death) or protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include those ≥24 hrs or involving a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular or atrial dysrhythmia, or stroke, that also require intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. In addition, MI or stroke during any hospitalization are included.</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints</title>
          <description>Treatment comparisons for time to first occurrence of composite outcome of all-cause death (composite outcome of death) or protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include those ≥24 hrs or involving a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular or atrial dysrhythmia, or stroke, that also require intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. In addition, MI or stroke during any hospitalization are included.</description>
          <population>Randomized Participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                    <measurement group_id="O2" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time Points</title>
        <description>Treatment comparisons for time to heart failure mortality or heart failure hospitalization</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Heart Failure Mortality or Heart Failure Hospitalization at Given Time Points</title>
          <description>Treatment comparisons for time to heart failure mortality or heart failure hospitalization</description>
          <population>Randomized Participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                    <measurement group_id="O2" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Month 6 and Month 14</title>
        <description>Mean score and adjusted mean change from baseline in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
        <time_frame>Baseline, Month 6, Month 14</time_frame>
        <population>Participants with baseline score and score at timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Month 6</title>
            <description>Cohort of participants in Placebo group with MLwHF scores at Baseline and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan - Month 6</title>
            <description>Cohort of participants in Irbesartan group with MLwHF scores at Baseline and Month 6</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Month 14</title>
            <description>Cohort of participants in Placebo group with MLwHF scores at Baseline and Month 14</description>
          </group>
          <group group_id="O4">
            <title>Irbesartan - Month 14</title>
            <description>Cohort of participants in Irbesartan group with MLwHF scores at Baseline and Month 14</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Month 6 and Month 14</title>
          <description>Mean score and adjusted mean change from baseline in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
          <population>Participants with baseline score and score at timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1550"/>
                <count group_id="O3" value="1434"/>
                <count group_id="O4" value="1428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="0.52"/>
                    <measurement group_id="O2" value="43.0" spread="0.53"/>
                    <measurement group_id="O3" value="42.7" spread="0.53"/>
                    <measurement group_id="O4" value="42.8" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Score at Timepoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="0.48"/>
                    <measurement group_id="O2" value="33.2" spread="0.50"/>
                    <measurement group_id="O3" value="31.6" spread="0.50"/>
                    <measurement group_id="O4" value="32.1" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="0.41"/>
                    <measurement group_id="O2" value="-9.8" spread="0.41"/>
                    <measurement group_id="O3" value="-11.2" spread="0.42"/>
                    <measurement group_id="O4" value="-10.6" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 2 treatment arms at Month 6 (first 2 columns)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>comparison of 2 treatment arms at Month 14 (columns 3 and 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Final Visit</title>
        <description>Mean score at baseline and final visit in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
        <time_frame>Baseline, Final Visit=last scheduled visit specified in the protocol at conclusion of the entire study by the sponsor. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <population>Participants with baseline score and score at timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Final Visit</title>
            <description>Cohort of participants in Placebo group with MLwHF scores at Baseline and Final Visit</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan - Final Visit</title>
            <description>Cohort of participants in Irbesartan group with MLwHF scores at Baseline and Final Visit</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure (MLwHF) Total Score (Sum of Questions 1-21) at Final Visit</title>
          <description>Mean score at baseline and final visit in Minnesota Living with Heart Failure (MLWHF) questionnaire, a 21-item, patient-reported, 6-point (ranging from 0-5; higher score=poorer quality of life; highest possible score=105) measurement of quality of life in persons with heart failure.</description>
          <population>Participants with baseline score and score at timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="0.49"/>
                    <measurement group_id="O2" value="38.9" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="0.51"/>
                    <measurement group_id="O2" value="38.3" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in B-Type Natriuretic Peptide (Pro-BNP) at Month 6 and Month 14</title>
        <description>Adjusted ratio to baseline in geometric mean in Pro-BNP in the blood. Ratio to Baseline = On-therapy geometric mean divided by baseline geometric mean. A lower score signifies improvement. Change from baseline adjusted for baseline value and angiotensin converting enzyme inhibitor use at baseline. Analysis uses natural logarithms of excretion rate values.</description>
        <time_frame>Baseline, Month 6, Month 14</time_frame>
        <population>number of participants with measurement at baseline and at timepoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Month 6</title>
            <description>Placebo cohort with measurements at baseline and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan - Month 6</title>
            <description>Irbesartan cohort with measurements at Baseline and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Month 14</title>
            <description>Placebo cohort with measurements at Baseline and Month 14.</description>
          </group>
          <group group_id="O4">
            <title>Irbesartan - Month 14</title>
            <description>Irbesartan cohort with measurements at Baseline and Month 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in B-Type Natriuretic Peptide (Pro-BNP) at Month 6 and Month 14</title>
          <description>Adjusted ratio to baseline in geometric mean in Pro-BNP in the blood. Ratio to Baseline = On-therapy geometric mean divided by baseline geometric mean. A lower score signifies improvement. Change from baseline adjusted for baseline value and angiotensin converting enzyme inhibitor use at baseline. Analysis uses natural logarithms of excretion rate values.</description>
          <population>number of participants with measurement at baseline and at timepoint</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1337"/>
                <count group_id="O3" value="1295"/>
                <count group_id="O4" value="1281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.023"/>
                    <measurement group_id="O2" value="0.93" spread="0.022"/>
                    <measurement group_id="O3" value="1.00" spread="0.026"/>
                    <measurement group_id="O4" value="1.01" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing CV Death, Non-Fatal Myocardial Infarction (MI), or Non-Fatal Stroke at Given Timepoints</title>
        <description>Treatment comparisons for time to cardiovascular death, non-fatal MI, or non-fatal stroke.</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing CV Death, Non-Fatal Myocardial Infarction (MI), or Non-Fatal Stroke at Given Timepoints</title>
          <description>Treatment comparisons for time to cardiovascular death, non-fatal MI, or non-fatal stroke.</description>
          <population>Randomized Participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Cardiovascular Death at Given Timepoints</title>
        <description>Treatment comparisons for time to cardiovascular death</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Cardiovascular Death at Given Timepoints</title>
          <description>Treatment comparisons for time to cardiovascular death</description>
          <population>Randomized Subjects</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing All-cause Death at Given Time Points</title>
        <description>Treatment comparisons for time to all-cause death</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing All-cause Death at Given Time Points</title>
          <description>Treatment comparisons for time to all-cause death</description>
          <population>Randomized subjects</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the New York Heart Association (NYHA) Functional Class at Month 6, Month 10, Month 14, and Final Visit</title>
        <description>NYHA functional classification=4-tiered system relating symptoms to everyday activities &amp; quality of life. (See Reporting Groups for description of each class.) Change of NYHA functional class from baseline was grouped into 3 categories: improved, unchanged, or worsened (based on case report form [CRF] assessment). If a post-randomization CRF assessment was missing or participant died, was hospitalized for worsening heart failure or discontinued study medication for worsening heart failure, the participant was classified as Major Event.</description>
        <time_frame>Baseline, Month 6, Month 10, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <population>Randomized participants with measurement at baseline and Month 6, Month 10, Month 14, and Final Visit</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan Baseline Class I or II</title>
            <description>Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan Class III or IV</title>
            <description>Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.</description>
          </group>
          <group group_id="O3">
            <title>Irbesartan Baseline All Classes Combined</title>
          </group>
          <group group_id="O4">
            <title>Placebo Baseline Class I or II</title>
          </group>
          <group group_id="O5">
            <title>Placebo Class III or IV</title>
          </group>
          <group group_id="O6">
            <title>Placebo Baseline All Classes Combined</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the New York Heart Association (NYHA) Functional Class at Month 6, Month 10, Month 14, and Final Visit</title>
          <description>NYHA functional classification=4-tiered system relating symptoms to everyday activities &amp; quality of life. (See Reporting Groups for description of each class.) Change of NYHA functional class from baseline was grouped into 3 categories: improved, unchanged, or worsened (based on case report form [CRF] assessment). If a post-randomization CRF assessment was missing or participant died, was hospitalized for worsening heart failure or discontinued study medication for worsening heart failure, the participant was classified as Major Event.</description>
          <population>Randomized participants with measurement at baseline and Month 6, Month 10, Month 14, and Final Visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="1641"/>
                <count group_id="O3" value="2067"/>
                <count group_id="O4" value="445"/>
                <count group_id="O5" value="1615"/>
                <count group_id="O6" value="2060"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="881"/>
                    <measurement group_id="O3" value="936"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="834"/>
                    <measurement group_id="O6" value="881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="656"/>
                    <measurement group_id="O3" value="966"/>
                    <measurement group_id="O4" value="338"/>
                    <measurement group_id="O5" value="678"/>
                    <measurement group_id="O6" value="1016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="904"/>
                    <measurement group_id="O3" value="948"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="860"/>
                    <measurement group_id="O6" value="902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294"/>
                    <measurement group_id="O2" value="617"/>
                    <measurement group_id="O3" value="911"/>
                    <measurement group_id="O4" value="317"/>
                    <measurement group_id="O5" value="622"/>
                    <measurement group_id="O6" value="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 - Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="895"/>
                    <measurement group_id="O3" value="933"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="863"/>
                    <measurement group_id="O6" value="902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="579"/>
                    <measurement group_id="O3" value="866"/>
                    <measurement group_id="O4" value="312"/>
                    <measurement group_id="O5" value="578"/>
                    <measurement group_id="O6" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="103"/>
                    <measurement group_id="O6" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="886"/>
                    <measurement group_id="O3" value="928"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="840"/>
                    <measurement group_id="O6" value="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="428"/>
                    <measurement group_id="O3" value="658"/>
                    <measurement group_id="O4" value="254"/>
                    <measurement group_id="O5" value="440"/>
                    <measurement group_id="O6" value="694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="324"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="254"/>
                    <measurement group_id="O6" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</title>
        <description>This was an assessment of the change in overall physician opinion of change from baseline status. Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
        <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</title>
          <description>This was an assessment of the change in overall physician opinion of change from baseline status. Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562"/>
                    <measurement group_id="O2" value="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                    <measurement group_id="O2" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528"/>
                    <measurement group_id="O2" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546"/>
                    <measurement group_id="O2" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442"/>
                    <measurement group_id="O2" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507"/>
                    <measurement group_id="O2" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430"/>
                    <measurement group_id="O2" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477"/>
                    <measurement group_id="O2" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364"/>
                    <measurement group_id="O2" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</title>
        <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
        <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Assessment of Heart Failure Status at Month 6, Month 14, and Final Visit Compared With Baseline</title>
          <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
          <population>Randomized Participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552"/>
                    <measurement group_id="O2" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529"/>
                    <measurement group_id="O2" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537"/>
                    <measurement group_id="O2" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532"/>
                    <measurement group_id="O2" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461"/>
                    <measurement group_id="O2" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396"/>
                    <measurement group_id="O2" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Event - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Assessment of Fatigue at Month 6, Month 14, and Final Visit Compared With Baseline</title>
        <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
        <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Assessment of Fatigue at Month 6, Month 14, and Final Visit Compared With Baseline</title>
          <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
          <population>Randomized Participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523"/>
                    <measurement group_id="O2" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504"/>
                    <measurement group_id="O2" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579"/>
                    <measurement group_id="O2" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513"/>
                    <measurement group_id="O2" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439"/>
                    <measurement group_id="O2" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525"/>
                    <measurement group_id="O2" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479"/>
                    <measurement group_id="O2" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Assessment of Dyspnea at Month 6, Month 14, and Final Visit Compared With Baseline</title>
        <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
        <time_frame>Baseline, Month 6, Month 14, Final Visit. The trial was designed to end after 1440 primary endpoint events, projected duration=6.0 ± 0.5 years.</time_frame>
        <population>Randomized Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Assessment of Dyspnea at Month 6, Month 14, and Final Visit Compared With Baseline</title>
          <description>Assessments are directly based on the Case Report Form (CRF). If the post-randomization CRF assessment was missing and the subject died, was hospitalized for worsening heart failure, or discontinued study medication for worsening heart failure, the subject was considered as having a Major Event. Participants who are summarized under Major Events are categorized as Worsened Markedly.</description>
          <population>Randomized Participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549"/>
                    <measurement group_id="O2" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512"/>
                    <measurement group_id="O2" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508"/>
                    <measurement group_id="O2" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519"/>
                    <measurement group_id="O2" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476"/>
                    <measurement group_id="O2" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 14 - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382"/>
                    <measurement group_id="O2" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Improved Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Moderately</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Worsened Markedly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - Major Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit - No Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing CV Death or CV Hospitalization at Given Timepoints</title>
        <description>Treatment comparisons for time to CV death or CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing CV Death or CV Hospitalization at Given Timepoints</title>
          <description>Treatment comparisons for time to CV death or CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
          <population>randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Protocol-specified Cardiovascular (CV) Hospitalization at Given Timepoints</title>
        <description>Treatment comparisons for time to protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Protocol-specified Cardiovascular (CV) Hospitalization at Given Timepoints</title>
          <description>Treatment comparisons for time to protocol-specified CV hospitalization. Protocol-specified CV hospitalizations include hospitalizations ≥24 hrs or involve a calendar date change for a primary cause of worsening heart failure, unstable angina, myocardial infarction, ventricular dysrhythmia, atrial dysrhythmia or stroke that also requires intravenous or intramuscular therapy or a related procedure or significant augmentation of oral therapy. Protocol specified CV hospitalizations also include myocardial infarction or stroke occurring during any hospitalization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2067"/>
                <count group_id="O2" value="2061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Onset of Diabetes Among Subjects With No Prior Diabetes History at Given Timepoints</title>
        <description>Treatment comparisons for time to new onset of diabetes (from adverse event reporting) among subjects with no prior history of diabetes.</description>
        <time_frame>Year 1, Year 2, Year 3, Year 4, Year 5</time_frame>
        <population>Randomized participants with no prior diabetes history</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Onset of Diabetes Among Subjects With No Prior Diabetes History at Given Timepoints</title>
          <description>Treatment comparisons for time to new onset of diabetes (from adverse event reporting) among subjects with no prior history of diabetes.</description>
          <population>Randomized participants with no prior diabetes history</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1495"/>
                <count group_id="O2" value="1496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage at 1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 3 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage at 5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Glomerular Filtration Rate (GFR) at Month 6, Month 18, and Month 30</title>
        <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
        <time_frame>Baseline, Month 6, Month 18, Month 30</time_frame>
        <population>Participants with baseline score and score at timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Month 6</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan - Month 6</title>
            <description>Cohort of participants in irbesartan group with GFR assessment at Baseline and Month 6</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Month 18</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 18</description>
          </group>
          <group group_id="O4">
            <title>Irbesartan - Month 18</title>
            <description>Cohort of participants in irbesartan group with GFR assessment at Baseline and Month 18</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Month 30</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 30</description>
          </group>
          <group group_id="O6">
            <title>Irbesartan - Month 30</title>
            <description>Cohort of participants in irbesartan group with GFR assessment at Baseline and Month 30</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Glomerular Filtration Rate (GFR) at Month 6, Month 18, and Month 30</title>
          <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
          <population>Participants with baseline score and score at timepoint.</population>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1741"/>
                <count group_id="O2" value="1734"/>
                <count group_id="O3" value="1406"/>
                <count group_id="O4" value="1379"/>
                <count group_id="O5" value="1270"/>
                <count group_id="O6" value="1225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.02" spread="0.536"/>
                    <measurement group_id="O2" value="73.13" spread="0.538"/>
                    <measurement group_id="O3" value="73.58" spread="0.589"/>
                    <measurement group_id="O4" value="73.49" spread="0.591"/>
                    <measurement group_id="O5" value="73.34" spread="0.606"/>
                    <measurement group_id="O6" value="74.37" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.97" spread="0.527"/>
                    <measurement group_id="O2" value="69.21" spread="0.562"/>
                    <measurement group_id="O3" value="70.88" spread="0.583"/>
                    <measurement group_id="O4" value="68.00" spread="0.596"/>
                    <measurement group_id="O5" value="69.51" spread="0.589"/>
                    <measurement group_id="O6" value="67.05" spread="0.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.393"/>
                    <measurement group_id="O2" value="-3.91" spread="0.394"/>
                    <measurement group_id="O3" value="-2.69" spread="0.436"/>
                    <measurement group_id="O4" value="-5.50" spread="0.440"/>
                    <measurement group_id="O5" value="-4.02" spread="0.442"/>
                    <measurement group_id="O6" value="-7.12" spread="0.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Glomerular Filtration Rate (GFR)at Month 42, Month 54, Month 66</title>
        <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
        <time_frame>Baseline, Month 42, Month 54, Month 66</time_frame>
        <population>Participants with baseline score and score at timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Month 42</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 42</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan - Month 42</title>
            <description>Cohort of participants in irbesartan group with GFR assessment at Baseline and Month 42</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Month 54</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 54</description>
          </group>
          <group group_id="O4">
            <title>Irbesartan - Month 54</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 54</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Month 66</title>
            <description>Cohort of participants in Placebo group with GFR assessment at Baseline and Month 66</description>
          </group>
          <group group_id="O6">
            <title>Irbesartan - Month 66</title>
            <description>Cohort of participants in irbesartan group with GFR assessment at Baseline and Month 66</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Glomerular Filtration Rate (GFR)at Month 42, Month 54, Month 66</title>
          <description>Based on the Cockcroft-Gault formula calculation, a commonly used surrogate marker to estimate creatinine clearance, which in turn is an approximate measure of GFR. It employs serum creatinine measurements and a patient's weight to predict the creatinine clearance. Adjusted for baseline GFR and angiotensin-converting enzyme inhibitor use at baseline (ACE-I). A decrease from baseline signifies worsening. The adjusted mean change from baseline value is from the model (calculated prior to rounding), whereas the other two points are the baseline mean and post mean.</description>
          <population>Participants with baseline score and score at timepoint.</population>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="928"/>
                <count group_id="O2" value="921"/>
                <count group_id="O3" value="429"/>
                <count group_id="O4" value="455"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.37" spread="0.715"/>
                    <measurement group_id="O2" value="74.95" spread="0.711"/>
                    <measurement group_id="O3" value="75.29" spread="1.075"/>
                    <measurement group_id="O4" value="75.17" spread="1.052"/>
                    <measurement group_id="O5" value="63.47" spread="5.596"/>
                    <measurement group_id="O6" value="71.84" spread="5.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.34" spread="0.700"/>
                    <measurement group_id="O2" value="67.48" spread="0.715"/>
                    <measurement group_id="O3" value="72.65" spread="1.048"/>
                    <measurement group_id="O4" value="68.24" spread="1.055"/>
                    <measurement group_id="O5" value="60.09" spread="5.832"/>
                    <measurement group_id="O6" value="64.85" spread="6.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjusted Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="0.559"/>
                    <measurement group_id="O2" value="-7.36" spread="0.561"/>
                    <measurement group_id="O3" value="-2.63" spread="0.863"/>
                    <measurement group_id="O4" value="-6.93" spread="0.838"/>
                    <measurement group_id="O5" value="-4.91" spread="4.534"/>
                    <measurement group_id="O6" value="-5.46" spread="4.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Onset Atrial Fibrillation (AF) Among Those With No Prior AF History or Evidence of AF on Baseline Electrocardiograph (ECG)</title>
        <description>Frequency of new onset AF in participants with no prior AF history or evidence of AF on baseline ECG. Stratified by use of angiotensin-converting enzyme (ACE) inhibitors and measured by adverse events reporting and final ECG recording read by the investigator.</description>
        <time_frame>Baseline, Final Visit</time_frame>
        <population>Randomized subjects (total=4128) with no prior AF history or evidence of AF on baseline ECG, stratified by use of ACE-I</population>
        <group_list>
          <group group_id="O1">
            <title>Irbesartan + ACE-I Use</title>
          </group>
          <group group_id="O2">
            <title>Placebo + ACE-I Use</title>
          </group>
          <group group_id="O3">
            <title>Irbesartan no ACE-I Use</title>
          </group>
          <group group_id="O4">
            <title>Placebo no ACE-I Use</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Onset Atrial Fibrillation (AF) Among Those With No Prior AF History or Evidence of AF on Baseline Electrocardiograph (ECG)</title>
          <description>Frequency of new onset AF in participants with no prior AF history or evidence of AF on baseline ECG. Stratified by use of angiotensin-converting enzyme (ACE) inhibitors and measured by adverse events reporting and final ECG recording read by the investigator.</description>
          <population>Randomized subjects (total=4128) with no prior AF history or evidence of AF on baseline ECG, stratified by use of ACE-I</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="510"/>
                <count group_id="O3" value="1529"/>
                <count group_id="O4" value="1551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No prior AF history or Evidence on Baseline ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="344"/>
                    <measurement group_id="O3" value="1089"/>
                    <measurement group_id="O4" value="1102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with New Onset Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: from start of study through last treatment +30 days; AEs: through the last dose +1 day.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IRBESARTAN</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
        <group group_id="E2">
          <title>PLACEBO</title>
          <description>titration from 75 to 300 mg, once daily (QD), up to 6 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1146" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1155" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOCHROMIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPONTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY MEDIASTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANAEMIA VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="274" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINOATRIAL BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BIFASCICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONDUCTION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADAMS-STOKES SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PAROXYSMAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHORDAE TENDINAE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY OSTIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SILENT MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DECONDITIONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HIP DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PRESBYACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MOTION SICKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THYROIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THYROID DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IRIDOCYCLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MACULAR RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATROPHY OF GLOBE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLINDNESS UNILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORNEAL DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>APHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SIGMOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMORAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DUODENAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTESTINAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MECHANICAL ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EROSIVE DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLONIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATIC NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MESENTERIC OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTESTINAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PAPILLA OF VATER STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BOWEL MOVEMENT IRREGULARITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMORAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THROMBOSIS MESENTERIC VESSEL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL STRANGULATED HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NODULE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENANTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADVERSE EVENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERFORATED ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIPHERAL COLDNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TEMPERATURE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRUG CHEMICAL INCOMPATIBILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MECHANICAL COMPLICATION OF IMPLANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BILIARY FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYDROCHOLECYSTIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BILIARY DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATORENAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATITIS CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AMPULLA OF VATER STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>IODINE ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARBUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PYOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URETHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SINOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ECHINOCOCCIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CELLULITIS ORBITAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABSCESS SOFT TISSUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FUNGAL OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OTICUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NOSOCOMIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERITONEAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN GRAFT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERITONSILLAR ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INFECTED VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEAT STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANIMAL SCRATCH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ILIUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETINAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUTURE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EYEBALL RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKELETAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>STERNAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BURNS THIRD DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EXTRADURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMATURIA TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEMICAL BURN OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EXPOSURE TO TOXIC AGENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TRACHEOSTOMY MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEVICE ELECTRICAL FINDING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF JOINT PROSTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANGIOGRAM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEST X-RAY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD ALCOHOL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COAGULATION TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY RATE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARCINOEMBRYONIC ANTIGEN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SCAN MYOCARDIAL PERFUSION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE ORTHOSTATIC ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FOLATE DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPEROSMOLAR STATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METABOLIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TYPE 1 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SCOLIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPONDYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GOUTY TOPHUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METATARSALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCLE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FLOATING PATELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACQUIRED CLAW TOE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOWER LIMB DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LIP NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BONE NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEOPLASM SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TONSIL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADENOMA BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRAIN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THYROID ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TRACHEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URETHRAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADRENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OVARIAN NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PLEURAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEOPLASM PROSTATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABDOMINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GALLBLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASES TO SPINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASES TO PLEURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BENIGN BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALIGNANT MUSCLE NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTATIC GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BENIGN MEDIASTINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MYELOPROLIFERATIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALIGNANT FIBROUS HISTIOCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MALIGNANT URINARY TRACT NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WALDENSTROM'S MACROGLOBULINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LENTIGO MALIGNA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METASTATIC SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA TRANSFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOTONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MONOPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MONOPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DROP ATTACKS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GLOBAL AMNESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBROSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MENTAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MOTOR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MYASTHENIA GRAVIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RADICULAR SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>WALLENBERG SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBELLAR HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBRAL ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VERTEBROBASILAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SOPOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NERVOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSTHYMIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERSONALITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SOCIAL AVOIDANT BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OBSESSIVE-COMPULSIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHROSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>COLPOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BREAST MASS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CERVIX DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>GENITAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PROSTATIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>UTERINE CERVIX STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ORTHOPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYDROTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ASTHMATIC CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPNOEA AT REST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NOCTURNAL DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PLEURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY HILUM MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHIAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEYNE-STOKES RESPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DRY GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PARAPSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SKIN NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ERYTHEMA NODOSUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA FACIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LIPODYSTROPHY ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE SUBCUTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOCLASTIC VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HOSPITALISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY BYPASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS SHUNT OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANGIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ANEURYSM RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>TEMPORAL ARTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VARICOSE ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL STENOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ESSENTIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIABETIC VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS OBLITERANS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>VISCERAL ARTERIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1255" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="1191" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="253" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="2062"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="2064"/>
                <counts group_id="E2" subjects_affected="252" subjects_at_risk="2062"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Britol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

